Silverarc Capital Management
BOSTON, MAfiles as SILVERARC CAPITAL MANAGEMENT, LLC
$899m in 65 US stocks at the end of 30 June 2026. The top 10 are 45.3% of the money. It changed about 38.8% of the portfolio this quarter.
Value
$899m
Stocks
65
Top 10 share
45.3%
Turnover
38.8%
What changed this quarter
New
Bought for the first time this quarter.
- Ascendis Pharma A/SASND6.1% of the fund
- Enliven TherapeuticsELVN2.8% of the fund
- Sagimet BiosciencesSGMT2.5% of the fund
- Definium TherapeuticsDFTX2.1% of the fund
- ALX Oncology HoldingsALXO1.3% of the fund
- VeradermicsMANE1.3% of the fund
- Avalyn PharmaAVLN1.2% of the fund
- Aclaris TherapeuticsACRS1.1% of the fund
- Avalo TherapeuticsAVTX1.0% of the fund
- GeneDx HoldingsWGS0.9% of the fund
- Solid BiosciencesSLDB0.7% of the fund
- Artiva BiotherapeuticsARTV0.6% of the fund
- uniQureQURE0.5% of the fund
- Research Alliance Corp IIIRACC0.4% of the fund
- Karyopharm TherapeuticsKPTI0.3% of the fund
- Revolution MedicinesRVMD0.2% of the fund
- Achieve Life SciencesACHV0.2% of the fund
- Connect Biopharma HoldingsCNTB0.1% of the fund
- Cellectar BiosciencesCLRB<0.1% of the fund
- Foghorn TherapeuticsFHTX<0.1% of the fund
Added
Bought more of a stock they already held.
- CelcuityCELC5.8% of the fund+40%
- ImmunomeIMNM4.8% of the fund+9%
- Oruka TherapeuticsORKA3.7% of the fund+134%
- Syndax PharmaceuticalsSNDX3.0% of the fund+37%
- ImmunovantIMVT2.7% of the fund+49%
- VeracyteVCYT2.1% of the fund+77%
- C4 TherapeuticsCCCC1.6% of the fund+59%
- Trevi TherapeuticsTRVI1.4% of the fund+33%
- CerusCERS1.1% of the fund+9%
- Ovid TherapeuticsOVID0.9% of the fund+210%
- COMPASS PathwaysCMPS0.8% of the fund+68%
- iBioIBIO0.7% of the fund+1458%
- Sionna TherapeuticsSION0.2% of the fund+8%
Cut
Sold some of their stake.
- Cogent BiosciencesCOGT5.5% of the fund-3%
- UroGen PharmaURGN5.3% of the fund-13%
- Dianthus TherapeuticsDNTH4.2% of the fund-40%
- Monte Rosa TherapeuticsGLUE3.0% of the fund-45%
- ErascaERAS2.6% of the fund-32%
- Abivax SAABVX2.5% of the fund-44%
- Praxis Precision MedicinesPRAX2.4% of the fund-8%
- Kodiak SciencesKOD2.4% of the fund-45%
- Zenas BioPharmaZBIO1.4% of the fund-55%
- Helix Acquisition Corp. IIIHLXC1.4% of the fund-3%
- Xenon PharmaceuticalsXENE1.3% of the fund-6%
- BiogenBIIB1.2% of the fund-6%
- Benitec BiopharmaBNTC1.0% of the fund-5%
- SavaraSVRA0.9% of the fund-5%
- Oric PharmaceuticalsORIC0.9% of the fund-33%
- CompugenCGEN0.8% of the fund-4%
- Disc MedicineIRON0.7% of the fund-58%
- Alkermes plc.ALKS0.7% of the fund-75%
- Spyre TherapeuticsSYRE0.6% of the fund-68%
- Abeona TherapeuticsABEO0.4% of the fund-6%
- InsmedINSM0.4% of the fund-4%
- ElutiaELUT0.2% of the fund-12%
- TELA BioTELA0.2% of the fund-5%
- Fractyl HealthGUTS0.1% of the fund-4%
- Crescent BiopharmaCBIO0.1% of the fund-55%
Sold out
Sold their entire stake.
- Kalvista Pharmaceuticals-100%
- Nuvalent-100%
- Ascendis Pharma A/SASND-100%
- Centessa Pharmaceuticals-100%
- Scholar Rock HoldingSRRK-100%
- CG OncologyCGON-100%
- Celldex TherapeuticsCLDX-100%
- CytokineticsCYTK-100%
- Climb BioCLYM-100%
- Compass TherapeuticsCMPX-100%
- SurrozenSRZN-100%
- Zura BioZURA-100%
- Fulcrum TherapeuticsFULC-100%
- AnnexonANNX-100%
- Monopar TherapeuticsMNPR-100%
- NextCureNXTC-100%
- Neumora TherapeuticsNMRA-100%
- Edgewise TherapeuticsEWTX-100%
- Replimune GroupREPL-100%
- Generate BiomedicinesGENB-100%
- Radiopharm TheranosticsRADX-100%
- Aardvark TherapeuticsAARD-100%
Holdings
- Abivax SAABVX
- Share
- 2.5%
- Value
- $23m
- Shares
- 169,593
-44%
- Helix Acquisition Corp. IIIHLXC
- Share
- 1.4%
- Value
- $13m
- Shares
- 1,177,821
-3%
- Avalyn PharmaAVLN
- Share
- 1.2%
- Value
- $11m
- Shares
- 330,487
New
- Research Alliance Corp IIIRACC
- Share
- 0.4%
- Value
- $4m
- Shares
- 360,000
New
- Rocket Pharmaceuticals
- Share
- <0.1%
- Value
- $356
- Shares
- 104,828
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Ascendis Pharma A/SASND | 6.1% | $55m | 206,234 | New |
| CelcuityCELC | 5.8% | $52m | 500,996 | +40% |
| Cogent BiosciencesCOGT | 5.5% | $50m | 1,280,707 | -3% |
| UroGen PharmaURGN | 5.3% | $48m | 1,301,979 | -13% |
| ImmunomeIMNM | 4.8% | $43m | 2,017,009 | +9% |
| Dianthus TherapeuticsDNTH | 4.2% | $38m | 390,000 | -40% |
| Rhythm PharmaceuticalsRYTM | 3.8% | $35m | 311,461 | Held |
| Oruka TherapeuticsORKA | 3.7% | $34m | 352,802 | +134% |
| Monte Rosa TherapeuticsGLUE | 3.0% | $27m | 1,108,295 | -45% |
| Syndax PharmaceuticalsSNDX | 3.0% | $27m | 1,214,390 | +37% |
| Enliven TherapeuticsELVN | 2.8% | $25m | 489,382 | New |
| ImmunovantIMVT | 2.7% | $24m | 619,096 | +49% |
| ErascaERAS | 2.6% | $23m | 1,263,026 | -32% |
| Sagimet BiosciencesSGMT | 2.5% | $23m | 2,927,698 | New |
| Abivax SAABVX | 2.5% | $23m | 169,593 | -44% |
| Praxis Precision MedicinesPRAX | 2.4% | $22m | 65,679 | -8% |
| Kodiak SciencesKOD | 2.4% | $21m | 546,256 | -45% |
| Definium TherapeuticsDFTX | 2.1% | $19m | 400,000 | New |
| VeracyteVCYT | 2.1% | $19m | 318,001 | +77% |
| Guardant HealthGH | 1.7% | $15m | 99,826 | Held |
| C4 TherapeuticsCCCC | 1.6% | $14m | 3,032,060 | +59% |
| Zenas BioPharmaZBIO | 1.4% | $13m | 509,789 | -55% |
| Trevi TherapeuticsTRVI | 1.4% | $13m | 678,095 | +33% |
| Helix Acquisition Corp. IIIHLXC | 1.4% | $13m | 1,177,821 | -3% |
| ALX Oncology HoldingsALXO | 1.3% | $12m | 5,744,757 | New |
| VeradermicsMANE | 1.3% | $12m | 95,000 | New |
| Xenon PharmaceuticalsXENE | 1.3% | $11m | 186,821 | -6% |
| Avalyn PharmaAVLN | 1.2% | $11m | 330,487 | New |
| BiogenBIIB | 1.2% | $10m | 48,101 | -6% |
| Aclaris TherapeuticsACRS | 1.1% | $10m | 1,946,482 | New |
| CerusCERS | 1.1% | $10m | 3,472,737 | +9% |
| Avalo TherapeuticsAVTX | 1.0% | $9m | 500,402 | New |
| Benitec BiopharmaBNTC | 1.0% | $9m | 679,826 | -5% |
| VaxcytePCVX | 0.9% | $8m | 145,000 | Held |
| GeneDx HoldingsWGS | 0.9% | $8m | 122,269 | New |
| SavaraSVRA | 0.9% | $8m | 1,355,459 | -5% |
| Ovid TherapeuticsOVID | 0.9% | $8m | 3,101,129 | +210% |
| Oric PharmaceuticalsORIC | 0.9% | $8m | 738,873 | -33% |
| COMPASS PathwaysCMPS | 0.8% | $7m | 503,382 | +68% |
| CompugenCGEN | 0.8% | $7m | 3,184,257 | -4% |
| Solid BiosciencesSLDB | 0.7% | $7m | 668,450 | New |
| iBioIBIO | 0.7% | $6m | 3,520,490 | +1458% |
| Disc MedicineIRON | 0.7% | $6m | 82,800 | -58% |
| Alkermes plc.ALKS | 0.7% | $6m | 113,494 | -75% |
| Spyre TherapeuticsSYRE | 0.6% | $5m | 59,959 | -68% |
| Artiva BiotherapeuticsARTV | 0.6% | $5m | 525,000 | New |
| Contineum TherapeuticsCTNM | 0.5% | $5m | 296,135 | Held |
| uniQureQURE | 0.5% | $5m | 105,000 | New |
| Research Alliance Corp IIIRACC | 0.4% | $4m | 360,000 | New |
| Abeona TherapeuticsABEO | 0.4% | $4m | 610,407 | -6% |
| InsmedINSM | 0.4% | $4m | 34,438 | -4% |
| Karyopharm TherapeuticsKPTI | 0.3% | $3m | 297,460 | New |
| Camp4 TherapeuticsCAMP | 0.3% | $3m | 653,594 | Held |
| ElutiaELUT | 0.2% | $2m | 2,192,980 | -12% |
| Revolution MedicinesRVMD | 0.2% | $2m | 10,000 | New |
| Sionna TherapeuticsSION | 0.2% | $2m | 42,478 | +8% |
| TELA BioTELA | 0.2% | $2m | 2,137,201 | -5% |
| Achieve Life SciencesACHV | 0.2% | $1m | 227,178 | New |
| Fractyl HealthGUTS | 0.1% | $1m | 1,637,976 | -4% |
| Connect Biopharma HoldingsCNTB | 0.1% | $1m | 545,000 | New |
| Crescent BiopharmaCBIO | 0.1% | $1m | 59,104 | -55% |
| Cellectar BiosciencesCLRB | <0.1% | $894,404 | 321,728 | New |
| Foghorn TherapeuticsFHTX | <0.1% | $224,358 | 45,975 | New |
| Adagio Medical HoldingsADGM | <0.1% | $146,193 | 224,360 | -11% |
| Rocket Pharmaceuticals | <0.1% | $356 | 104,828 | Held |
Options (8)
- ARK ETF TR
- Type
- Put
- Value
- $21m
- Contracts
- 500,000
- Syndax Pharmaceuticals
- Type
- Call
- Value
- $15m
- Contracts
- 693,600
- Oric Pharmaceuticals
- Type
- Call
- Value
- $7m
- Contracts
- 682,600
- Monte Rosa Therapeutics
- Type
- Call
- Value
- $7m
- Contracts
- 300,000
- Abivax SA
- Type
- Call
- Value
- $7m
- Contracts
- 50,000
- Kymera Therapeutics
- Type
- Put
- Value
- $3m
- Contracts
- 25,000
- Absci
- Type
- Put
- Value
- $2m
- Contracts
- 157,600
- Fulcrum Therapeutics
- Type
- Call
- Value
- $1m
- Contracts
- 391,900
| Company | Type | Value | Contracts |
|---|---|---|---|
| ARK ETF TR | Put | $21m | 500,000 |
| Syndax Pharmaceuticals | Call | $15m | 693,600 |
| Oric Pharmaceuticals | Call | $7m | 682,600 |
| Monte Rosa Therapeutics | Call | $7m | 300,000 |
| Abivax SA | Call | $7m | 50,000 |
| Kymera Therapeutics | Put | $3m | 25,000 |
| Absci | Put | $2m | 157,600 |
| Fulcrum Therapeutics | Call | $1m | 391,900 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 83.9% since 30 June 2025.
Where the money is
Health care96.1%
Financial services1.4%
Other2.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.